ARCHIVES

Rosenberg Starts New Study With TIL; LAK-IL-2 Costs Clarified

This article is from The Cancer Letter archive.

Vol. 12 No. 46 | November 28, 1986

Download PDF Visit The Full Archive

Related Articles

HHS Task Force Says NCI Drug Program Effective, Otters Suggestions; DeVita Responds

March 26, 1982

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

January 25, 2002

New Clinical Trials Monitoring Program To Site Visit PIs Every Three Years

July 30, 1982

Hammer Says “Exciting Times” Should Convince President to Increase Budget, Ok Act Renewal

April 26, 1985

Senate Appropriators Reject President’s $228 Million Increase For Cancer Research; House and Senate Report Language

September 18, 2009

Program Committee Lists 10 Papers At AACR Meeting

July 19, 1985